written on 09.06.2014
Tags:
,

Merck snatches Idenix for $3.8B as it watches Sovaldi gobble up market share

TAGS: ,

Sovaldi's runaway success looms large over Merck's decision to ante up $3.8 billion to buy Idenix Pharmaceuticals, which has three hepatitis C drugs in early stage development. Gilead's hep C drug has given an early peek at just how large the market is and how extensive it will be for years to come, an opportunity Merck hopes to exploit by acquiring more hep C firepower.

Latest Report